{"schema_version":"1","generated_at":"2026-11-11T00:29:00.465Z","data_as_of":null,"url":"https://www.findmykol.com/kol/shakir-sarwar","json_url":"https://www.findmykol.com/kol/shakir-sarwar/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"shakir-sarwar","name":"Shakir Sarwar","credential":"MD","specialty":"Hematology / Oncology","specialty_raw":"Hematology & Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"Grant Medical Center","institution_url":"https://www.findmykol.com/institution/grant-medical-center","city":"Westerville","state":"OH","region":{"label":"Midwest","url":"https://www.findmykol.com/region/midwest"}},"identifiers":{"npi":"1609827989","openalex":"A5005966778"},"summary":"Shakir Sarwar is an Oncology physician affiliated with Grant Medical Center. OpenAlex indexes 5 publications with 423 citations (h-index 4).","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":5,"cited_by_count":423,"h_index":4,"latest_activity_year":2025,"source":"works"},"payments":{"company_count":14,"program_years":{"first":2021,"last":null},"rows_total":22,"shown":3,"withheld":19,"rows":[{"payer":"AstraZeneca Pharmaceuticals LP","program_year":2025,"amount_usd":55.49,"payment_count":2,"source_url":"https://openpaymentsdata.cms.gov/search?query=1609827989"},{"payer":"PFIZER INC.","program_year":2025,"amount_usd":40.8,"payment_count":2,"source_url":"https://openpaymentsdata.cms.gov/search?query=1609827989"},{"payer":"Novartis Pharmaceuticals Corporation","program_year":2025,"amount_usd":30.43,"payment_count":2,"source_url":"https://openpaymentsdata.cms.gov/search?query=1609827989"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1609827989","source":"payments"},"prescribing":{"data_year":2024,"areas_total":10,"areas_shown":3,"areas":[{"area":"Cancer & immunology","share_pct":52.2,"classes_total":10,"classes":[{"class":"Kinase inhibitor","setting":"prescribed","share_pct":16.3,"drugs":[{"name":"Verzenio","share_pct":23.5},{"name":"Tasigna","share_pct":22.2},{"name":"Imatinib Mesylate","share_pct":17.3},{"name":"Ibrance","share_pct":15.4},{"name":"Brukinsa","share_pct":7.4},{"name":"Imbruvica","share_pct":7.4},{"name":"Tagrisso","share_pct":6.8}],"max_beneficiaries":null},{"class":"Aromatase Inhibitor","setting":"prescribed","share_pct":11.2,"drugs":[{"name":"Anastrozole","share_pct":77.7},{"name":"Letrozole","share_pct":22.3}],"max_beneficiaries":null}]},{"area":"Metabolism & gastrointestinal","share_pct":14.6,"classes_total":3,"classes":[{"class":"Serotonin-3 Receptor Antagonist","setting":"prescribed","share_pct":6.9,"drugs":[{"name":"Ondansetron Hcl","share_pct":79.7},{"name":"Ondansetron Odt","share_pct":20.3}],"max_beneficiaries":null},{"class":"Corticosteroid","setting":"prescribed","share_pct":4.9,"drugs":[{"name":"Prednisone","share_pct":100}],"max_beneficiaries":18}]},{"area":"Nervous system","share_pct":12.2,"classes_total":3,"classes":[{"class":"Phenothiazine","setting":"prescribed","share_pct":6.3,"drugs":[{"name":"Prochlorperazine Maleate","share_pct":100}],"max_beneficiaries":47},{"class":"Gabapentinoids","setting":"prescribed","share_pct":3.3,"drugs":[{"name":"Gabapentin","share_pct":100}],"max_beneficiaries":13}]}],"care_setting":{"dominant":"mixed","data_year":2024,"office_pct":44.4,"facility_pct":55.6},"source":"medicare"},"publications":{"total":5,"shown":5,"withheld":0,"matched_by":"OpenAlex author record","recent":[{"title":"Burkitt’s lymphoma presenting as multiple nerve sheath tumors of the cauda equina","year":2025,"journal":"Surgical Neurology International","source_url":"https://doi.org/10.25259/sni_701_2021","status":"verified"},{"title":"Long-term outcomes of dual vs single HER2-directed neoadjuvant therapy in NSABP B-41","year":2023,"journal":"Breast Cancer Research and Treatment","source_url":"https://doi.org/10.1007/s10549-023-06881-8","status":"verified"},{"title":"Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: 5-year outcomes of NSABP protocol B-41.","year":2016,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.2016.34.15_suppl.501","status":"verified"},{"title":"A Case of a Bilateral Inflammatory Breast Cancer: A Case Report","year":2016,"journal":"The Breast Journal","source_url":"https://doi.org/10.1111/tbj.12578","status":"verified"},{"title":"Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial","year":2013,"journal":"The Lancet Oncology","source_url":"https://doi.org/10.1016/s1470-2045(13)70411-x","status":"verified"}],"source":"works"},"contact":{"address_1":"300 POLARIS PKWY","address_2":"SUITE 2500","city":"Westerville","state":"OH","zip":"430827989","phone":"614-846-0044","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1609827989","source":"identity"},"similar":[{"name":"Vijay Chandnani","slug":"vijay-chandnani","institution":"Grant Medical Center","specialty":"Diagnostic Radiology","url":"https://www.findmykol.com/kol/vijay-chandnani","json_url":"https://www.findmykol.com/kol/vijay-chandnani/profile.json"},{"name":"Moni Stein","slug":"moni-stein","institution":"Grant Medical Center","specialty":"Vascular & Interventional Radiology","url":"https://www.findmykol.com/kol/moni-stein","json_url":"https://www.findmykol.com/kol/moni-stein/profile.json"},{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Beth Karlan","slug":"beth-karlan","institution":"University of California, Los Angeles","specialty":"Gynecologic Oncology","url":"https://www.findmykol.com/kol/beth-karlan","json_url":"https://www.findmykol.com/kol/beth-karlan/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":19}},"sources":{"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2022-01-05","collected_at":"2026-11-06T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2024}},"methodology_url":"https://www.findmykol.com/about#methodology"}